Author: Dino Mustafić

March 24, 2021 Off

Bayer’s NTRK fusion-positive tumor drug approved in Japan

By Dino Mustafić

Bayer has announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for larotrectinib, under the brand name Vitrakvi, for the treatment of Neurotrophic Tyrosine Receptor Kinase (NTRK) fusion-positive advanced or recurrent solid tumors.